-
Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and licensing agreement with US-based EQRx Inc. (NASDAQ: EQRX) concerning the epidermal growth factor receptor (EGFR) inhibitor Ameile (almonertinib). As a result, the Chinese company will regain research and development (R&D), manufacturing, and commercialization rights to…
-
Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China
•
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing Zenshine Pharmaceuticals Co., Ltd. The agreement grants Jumpcan exclusive promotion rights to Zenshine’s polymerase acidic (PA) inhibitor, ZX-7101A, for the agreed indication in China mainland. Financial Terms and Promotion RightsIn exchange for the exclusive promotion…
-
Gilead Sciences Inc. Reports 5% YOY Revenue Increase in Q2 2023 Financials
•
US-based pharmaceutical major Gilead Sciences Inc., (NASDAQ: GILD) has released its financial results for the second quarter of 2023, reporting a 5% year-on-year (YOY) increase in global revenues to USD 6.6 billion. Excluding sales of the COVID-19 drug Veklury (remdesivir), revenues were up 11% YOY to USD 6.3 billion. HIV…
-
Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials
•
US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second quarter of 2023, reporting a total revenue increase of 7% year-on-year (YOY) in constant exchange rate terms, reaching USD 7 billion. Double-Digit Growth from Key TherapiesAmgen’s double-digit growth was driven by a range of therapies,…
-
GSK Files Patent Infringement Lawsuit Against Pfizer’s RSV Vaccine Abrysvo
•
UK pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has taken US-based Pfizer Inc., (NYSE: PFE) to court, alleging that Pfizer’s recently approved respiratory syncytial virus (RSV) vaccine, Abrysvo, infringes upon the patents of GSK’s own RSV vaccine, Arexvy. According to the docket filed with the US District Court of Delaware, Abrysvo is…
-
Novartis AG and Ionis Pharmaceuticals Renew Collaboration on Lp(a)-Driven CVD Drug
•
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has returned to US-based Ionis Pharmaceuticals Inc., (NASDAQ: IONS) for a collaboration and license agreement aimed at the discovery, development, and commercialization of a novel drug for patients with lipoprotein(a) (Lp(a))-driven cardiovascular disease (CVD). Building on a Successful PartnershipNovartis and Ionis previously formed…
-
Grand Pharmaceutical Group Gets NMPA Approval for Generic Eplerenone for Hypertension
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of eplerenone, an aldosterone receptor antagonist. The drug, co-developed with Nanjing Cavendish Bioengineering Technology Co., Ltd., is indicated for the treatment of hypertension. Eplerenone:…
-
Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal
•
China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive rights to develop, regulate, manufacture, and commercialize InventisBio’s D-1553 in mainland China. The agreement also provides Chia Tai Tianqing with potential ex-China territorial rights based on future data-sharing, although no financial details have been disclosed.…
